The first confirmative evidence supporting SST-analogs’ antiproliferative effect with clinical importance was derived from recruiting acromegalic patients with GH-oversecreting pituitary adenomas in a multicenter randomized trial [16]. The gene discussed is GH1; the disease is pituitary gland adenoma.